UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported):

August 12, 2019 (August 6, 2019)

 

Rite Aid Corporation

(Exact name of registrant as specified in its charter)

 

Delaware

 

1-5742

 

23-1614034

(State or Other Jurisdiction
of Incorporation)

 

(Commission File Number)

 

(IRS Employer
Identification Number)

 

30 Hunter Lane, Camp Hill, Pennsylvania 17011

(Address of principal executive offices, including zip code)

 

(717) 761-2633

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o             Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o             Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o             Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o             Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which
registered

Common Stock, $1.00 par value

 

RAD

 

The New York Stock Exchange

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company     o

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     o

 

 

 


 

Item 5.02.              Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

(b)           As previously disclosed by Rite Aid Corporation (the “Company”), the Company entered into a separation agreement with John Standley, the Chief Executive Officer of the Company, pursuant to which Mr. Standley continued to serve as the Chief Executive Officer of the Company until the appointment of his successor.  In accordance with the terms of the separation agreement, Mr. Standley will cease employment as the Chief Executive Officer of the Company effective as of August 12, 2019, in connection with the appointment of his successor, Heyward Donigan.

 

(c)           The Board of Directors (the “Board”) of the Company appointed Ms. Donigan to serve as the new Chief Executive Officer, effective as of August 12, 2019.

 

Ms. Donigan, age 58, most recently served as the president and chief executive officer of Sapphire Digital.  Prior to joining Sapphire Digital in 2015, Ms. Donigan was the president and chief executive officer of Valueoptions, Inc. beginning in 2010. Earlier in her career, Ms. Donigan served as executive vice president and chief marketing officer at Premera Blue Cross, and served as senior vice president of all operations at Cigna Healthcare. She also held executive roles at General Electric, Empire BCBS and U.S. Healthcare, and previously served on the Board of Directors at several public companies, including Kindred Healthcare. Ms. Donigan earned a Masters of Public Administration from New York University and a bachelor’s degree in English from the University of Virginia. Ms. Donigan currently serves on the board of directors of SI-Bone, Inc., and previously served on the boards of directors of NxStage Medical, Inc. from 2016 to 2019 and Kindred Healthcare, Inc. from 2014 to 2018. The Board has selected Ms. Donigan to serve as the new chief executive officer and as a member of the Board because of her broad experience with general management, strategic planning, technology, product, operations, compliance and marketing/sales background, and her consistent track record of organic, profitable growth across a broad spectrum of the healthcare industry.

 

The Company has entered into an employment agreement with Ms. Donigan, dated as of August 8, 2019 (the “Employment Agreement”).  The Employment Agreement has an initial term of two (2) years commencing August 12, 2019, and thereafter will automatically renew for successive one (1) year terms unless either she or the Company gives prior notice of nonrenewal.  Pursuant to the Employment Agreement, Ms. Donigan will be paid an annual base salary of $1,000,000, she will be eligible for a target annual cash bonus opportunity equal to 200% of her base salary (pro-rated for the current 2020 fiscal year), and, beginning in the Company’s 2021 fiscal year, she will be granted annual long-term equity incentive awards with a grant date fair value equal to 450% of her base salary, consistent with the award issuances to other senior executives of the Company.  The Employment Agreement further provides that the Company will grant to Ms. Donigan an inducement award consisting of a restricted stock award with a grant date fair value equal to $2,000,000 (284,900 shares, which will vest in equal annual installments on each of the three (3) successive anniversaries of her commencement date), nonqualified stock options with a grant date fair value equal to $2,000,000 determined using the Black Scholes pricing method (502,913

 

2


 

options with an exercise price of $7.02, which will vest and become exercisable in equal installments on each of the four (4) successive anniversaries of her commencement date), a cash inducement award equal to $3,200,000, and an $85,000 relocation subsidy (provided that Ms. Donigan will be required to (i) repay the entirety of the cash inducement award and relocation subsidy in the event of certain terminations of her employment occurring on or prior to the first anniversary of her commencement date and (ii) $1,200,000 of the cash inducement award in the event of certain terminations of her employment occurring between the first and the second anniversary of her commencement date).  The restricted stock award and nonqualified stock options will be subject to the terms of the form of employment inducement award agreement referenced below.

 

The Employment Agreement provides that in the event the Company terminates Ms. Donigan’s employment without “cause” or Ms. Donigan terminates her employment for “good reason” (each as defined in the Employment Agreement), and subject to her execution of a release of claims, Ms. Donigan will receive: (i) an amount equal to two (2) times the sum of (x) her base salary plus (y) target annual bonus (which will be payable in equal installments, generally over a period of two (2) years following the date the release of claims becomes irrevocable); (ii) if earned, an annual bonus for the year in which the termination of employment occurs based on actual performance for the year, prorated to reflect the portion of the year elapsed prior to her termination of employment; (iii) a lump sum payment equal to the cost for twenty-four (24) months’ continuation of group health plan coverage as of the date of her termination of employment; and (iv) accelerated vesting of any then outstanding restricted stock awards and stock options that would have vested and become exercisable, as applicable, during the two (2) year period following the date of her termination of employment. The Employment Agreement also subjects Ms. Donigan to certain confidentiality obligations and certain noncompetition, noninterference and nonsolicitation restrictions for a period of twelve (12) months’ post-employment.

 

The foregoing description of the Employment Agreement and employment inducement award, respectively, is a summary of certain terms only and is qualified in its entirety by the full text of the Employment Agreement filed as Exhibit 10.1 hereto and the form of employment inducement award agreement filed as Exhibit 10.2 hereto, each of which is incorporated herein by reference.

 

(d)           On August 6, 2019, the Board increased the size of the Board from eight (8) to nine (9) directors and appointed Ms. Donigan as a member of the Board, effective as of August 12, 2019.  Ms. Donigan’s term will expire at the Company’s 2020 annual meeting of stockholders.

 

Ms. Donigan was not selected as a director pursuant to any arrangement or understanding with any other person.  Ms. Donigan has not been party to any reportable transactions with the Company pursuant to Item 404(a) of Regulation S-K.

 

3


 

Item 7.01.            Regulation FD Disclosure.

 

On August 12, 2019, the Company issued a press release announcing the matters described in Item 5.02. A copy of the Company’s press release is being furnished as Exhibit 99.1 to this Form 8-K.

 

The information (including Exhibit 99.1) being furnished pursuant to this “Item 7.01 Regulation FD Disclosure” shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act regardless of any general incorporation language in such filing.

 

Item 9.01.            Financial Statements and Exhibits.

 

(d) Exhibits.

 

 


* Certain schedules and/or exhibits to this agreement have been omitted pursuant to Item 601(b)(2) of Regulation S-K and Rite Aid Corporation agrees to furnish supplementally to the Securities and Exchange Commission a copy of any omitted schedule and/or exhibit upon request.

 

4


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereto duly authorized.

 

Date: August 12, 2019

By:

/s/ James J. Comitale

 

Name:

James J. Comitale

 

Title:

Senior Vice President, General Counsel

 

5


Exhibit 10.1

 

Execution Copy

 

EMPLOYMENT AGREEMENT

 

THIS EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of the 8th day of August, 2019 by and between Rite Aid Corporation, a Delaware corporation (the “Company”) and Heyward Donigan (“Executive”).

 

WHEREAS , Executive desires to provide the Company with her services and the Company desires to hire and employ Executive on the terms and subject to the conditions set forth herein.

 

NOW, THEREFORE , in consideration of the mutual representations, warranties, covenants and agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and Executive (individually a “Party” and together the “Parties”), intending to be legally bound, agree as follows:

 

1.              Term of Employment .

 

The term of Executive’s employment under this Agreement shall commence on August 12, 2019 (the “Commencement Date”) and, unless earlier terminated pursuant to Section 5 below, shall continue for a period ending on the date that is two (2) years following the Commencement Date (the “Original Term of Employment”).  The Original Term of Employment shall be automatically renewed for successive one (1) year terms (the “Renewal Terms”) unless at least one hundred eighty (180) days prior to the expiration of the Original Term of Employment or any Renewal Term, either Party notifies the other Party in writing that he or it is electing to terminate this Agreement at the expiration of the then current term of employment.  “Term” shall mean the Original Term of Employment and all Renewal Terms.

 

2.              Position and Duties.

 

2.1           Generally During the Term, (i) Executive shall serve as Chief Executive Officer of the Company and shall have such duties, responsibilities and authority as are customary for such position and such other titles, duties, responsibilities and authorities as shall be assigned by the Board of Directors of the Company (the “Board”) from time to time consistent with such position, and (ii) the Board shall take necessary action to increase the size of the Board and appoint Executive to fill the vacancy at its next meeting and Executive shall hold office until the next annual election of directors; subsequently, unless otherwise agreed with Executive, the Board shall nominate Executive to serve as a member of the Board.  Except as permitted by Section 2.2 or otherwise approved by the Board, Executive shall devote her full working time, attention, knowledge and skills faithfully and to the best of her ability, to the duties and responsibilities assigned by the Board in furtherance of the business affairs and activities of the Company and its subsidiaries, affiliates and strategic partners.  Executive shall report solely to the Board.  Contemporaneously with the termination of Executive’s employment for any reason, Executive shall automatically resign from all offices and positions she holds with the Company or any subsidiary without any further action on the part of Executive or the Company; provided,

 


 

however, that Executive agrees to execute any additional documents required or requested by the Company with respect to such resignations.

 

2.2           Other Activities .   Anything herein to the contrary notwithstanding, nothing in this Agreement shall preclude Executive from engaging in the following activities:  (i) serving on the board of directors of a reasonable number of trade associations and/or charitable organizations, subject to the approval of the Board which shall not be unreasonably withheld, (ii) engaging in charitable activities and community affairs, and (iii) managing her personal investments and affairs, provided that Executive’s activities pursuant to clauses (i), (ii) or (iii) do not violate Sections 6 or 7 below or materially interfere with the proper performance of her duties and responsibilities under this Agreement.  Executive shall at all times be subject to, observe and carry out such rules, regulations, policies, directions, and restrictions as the Company may from time to time establish for officers of the Company or employees generally.  Executive shall not be permitted to serve on board of directors of any public companies without the prior approval of the Board.

 

3.              Compensation .

 

3.1           Base Salary During the Term, as compensation for her services hereunder, Executive shall receive a salary at the annualized rate of One Million Dollars ($1,000,000) per year (“Base Salary” as may be adjusted from time to time, subject to Section 5.4), which shall be paid in accordance with the Company’s normal payroll practices and procedures, less such deductions or offsets required by applicable law or otherwise authorized by Executive.

 

3.2           Annual Performance Bonus Executive shall participate each fiscal year during the Term in the Company’s annual bonus plan as adopted and approved by the Board or the Compensation Committee of the Board (the “Compensation Committee”) from time to time.  For the current fiscal year (FY 2020), Executive’s annual target bonus opportunity pursuant to such plan shall equal two hundred percent (200%) (the “Annual Target Bonus”) of the Base Salary, subject to proration beginning with the fiscal period in which the Commencement Date falls, determined by multiplying the Annual Target Bonus by a fraction (x) the numerator of which is the number of fiscal periods (months) in which Executive is employed during the 2020 fiscal year, beginning with the month in which the Commencement Date occurs and (y) the denominator of which is 12.  For subsequent fiscal years, the Annual Target Bonus may be adjusted by the Compensation Committee (however, in no event shall it be less than 200% of Base Salary).  Payment of any bonus earned shall be made in accordance with the terms of the Company’s annual bonus plan as in effect for the year for which the bonus is earned.

 

3.3           Inducement and Equity Awards .

 

(a)           Employment Inducement Award — Restricted Stock .  As an inducement to commence employment with the Company, on the Commencement Date, Executive will be granted a number of shares of restricted Company Common Stock, par value $1.00 per share (“Company Stock”) (the “Restricted Stock”) determined by dividing $2,000,000 by the closing price of a share of Company Stock on the Commencement Date.  The vesting restrictions on the Restricted Stock shall lapse as to one-third (1/3) of the shares on each of the first three (3) anniversaries from the Commencement Date, subject to continued service on each

 

2


 

applicable vesting date, and the Restricted Stock shall otherwise be evidenced by and subject to the terms of the Employment Inducement Award Agreement.

 

(b)           Employment Inducement Award — Stock Options As a further inducement to commence employment with the Company, on the Commencement Date, Executive will be granted a number of non-qualified stock options to purchase shares of Company Stock (the “Stock Options”) valued at $2,000,000 in the aggregate on the date of grant, determined by the Company utilizing the Black Scholes option pricing model.  The Stock Options will have an exercise price equal to the fair market value of a share of Company Stock on the date of grant and shall vest and become exercisable as to one-quarter (1/4) of the Stock Options on each of the first four (4) anniversaries from the Commencement Date, subject to continued service on each applicable vesting date, and shall otherwise be evidenced by and subject to the terms of the Employment Inducement Award Agreement.

 

(c)           Cash Inducement Award .  In connection with the entry into this Agreement, Executive shall receive an inducement payment equal to Three Million Two Hundred Thousand Dollars ($3,200,000) (the “Cash Inducement Payment”), which shall be paid in cash within the first five (5) days after the Commencement Date, less such deductions or offsets required by applicable law or otherwise authorized by Executive.  The Cash Inducement Payment is subject to repayment to the Company within thirty (30) days after the Executive’s employment is terminated by the Company for Cause or by Executive without Good Reason (in either case, the “Repayment Deadline”) in the amount of the full pre-tax amount of the Cash Inducement Payment if such termination occurs on or before the first anniversary of the Commencement Date or in the amount of One Million Two Hundred Thousand Dollars ($1,200,000) if such termination occurs on or before the second anniversary of the Commencement Date and after the first anniversary of the Commencement Date.  In the event Executive does not repay the Company in full by the Repayment Deadline, if applicable, then the Company may, in its sole discretion, either (i) offset any other amounts payable to Executive by the Company or any of its affiliates in satisfaction of the full Cash Inducement Payment or (ii) cause Executive to forfeit (or otherwise recoup) any equity interests that Executive holds in respect of the Company or any of its affiliates in an amount equal to the full Cash Inducement Payment, in each case subject to applicable law.

 

(d)           Participation in the LTIP .  Executive will be eligible to participate during the Term in the Company’s 2014 Omnibus Equity Plan and any successor plan (the “LTIP”) beginning with the Company’s 2021 fiscal year.  Executive’s target long term incentive award under the LTIP will be equal to four hundred fifty percent (450%) of Executive’s Base Salary.  The terms and frequency, if any, of long-term incentive award issuances to Executive under the LTIP shall be consistent with the award issuances to senior executives of the Company generally, which shall be in the sole discretion of the Board.

 

4.              Additional Benefits .

 

4.1           Employee Benefits During the Term, Executive shall be eligible to participate in the employee benefit plans (including, but not limited to medical, dental and life insurance plans, short-term and long-term disability coverage, and 401(k) plans) in which officers of the Company are generally eligible to participate, subject to satisfaction of any eligibility

 

3


 

requirements and the other generally applicable terms of such plans.  Nothing in this Agreement shall prevent the Company from amending or terminating any employee benefit plans of the Company from time to time as the Company deems appropriate.

 

4.2           Expenses The Company shall reimburse Executive for any expenses reasonably incurred by her during the Term (and at any time during her employment thereafter), in furtherance of her duties hereunder, including travel, meals and accommodations (but excluding relocation expenses and commuting expenses), upon submission of vouchers or receipts and in compliance with such rules and policies relating thereto as the Company may from time to time adopt or as may be required in order to permit such payments to be taken as proper deductions by the Company or any subsidiary under the Internal Revenue Code of 1986, as amended, and the rules and regulations adopted pursuant thereto now or hereafter in effect (the “Code”).

 

4.3           Vacation Executive shall be entitled to twenty (20) days of paid vacation during each year of the Term, subject to applicable Company policies as in effect from time to time.

 

4.4           Automobile Allowance During the Term, the Company shall provide Executive with an automobile allowance of $1,000 per month.

 

4.5           Annual Financial Planning Allowance .   During the Term, the Company shall provide Executive with an annual executive planning allowance in the amount of $10,000.  The provisions of Section 16.3 shall apply to any payments or reimbursements made under this Section 4.5.

 

4.6           Indemnification The Company shall (a) indemnify and hold Executive harmless, to the full extent permitted under applicable law, for, from and against any and all losses, claims, costs, expenses, damages, liabilities or actions (including security holder actions, in respect thereof) relating to or arising out of Executive’s employment with and service as an officer of the Company during the Term and at all times thereafter; and (b) pay all reasonable costs, expenses and attorney’s fees incurred by Executive in connection with or relating to the defense of any such loss, claim, cost, expense, damage, liability or action, subject to Executive’s undertaking to repay in the event it is ultimately determined that Executive is not entitled to be indemnified by the Company.  Executive shall at all relevant times be covered as an insured under any director and officer liability insurance that covers members of the Board.  Following termination of Executive’s employment or service with the Company, the Company shall cause any director and officer liability insurance policies applicable to Executive prior to such termination of employment to remain in effect for six (6) years following the date of termination of employment. The provisions of Section 16.3 shall apply to any payments or reimbursements made under this Section 4.6.

 

4.7           Relocation Within five (5) days of the Commencement Date, the Company shall pay Executive, in a lump sum, the amount of Eighty Five Thousand Dollars ($85,000) (the “Relocation Subsidy”), less such deductions or offsets required by applicable law or otherwise authorized by Executive.  The Relocation Subsidy is subject to repayment to the Company within thirty (30) days after the Executive’s employment is terminated by the Company for Cause or by Executive without Good Reason in the amount of the full pre-tax amount of the

 

4


 

Relocation Subsidy if such termination occurs on or before the first anniversary of the Commencement Date.

 

5.              Termination .

 

5.1           Termination of Executive’s Employment by the Company for Cause .

 

The Company may terminate Executive’s employment hereunder for Cause (as defined below).  Such termination of employment shall be effected by written notice thereof delivered by the Company to Executive, indicating in reasonable detail the facts and circumstances alleged to provide a basis for such termination of employment, and shall be effective as of the date of such notice in accordance with Section 14 hereof.  “Cause, “ as determined in commercially reasonable good faith by a resolution adopted by the affirmative vote of a majority of the Board (after reasonable written notice to Executive setting forth in reasonable detail the specific conduct of Executive upon which the Board relies in reaching its determination, and a reasonable opportunity for Executive, together with her counsel, to be heard before the Board prior to making such determination), shall mean:  (i) Executive’s willful failure to perform the lawful duties or responsibilities of her position with the Company or any subsidiary, or failure to timely carry out any lawful and reasonable directive of the Board; (ii) Executive’s misappropriation of any funds or property of the Company or any subsidiary; (iii) the conduct by Executive which is a material violation of this Agreement or written Company Policy or which materially interferes with Executive’s ability to perform her duties; (iv) Executive’s engaging in conduct constituting, or which could reasonably constitute, unlawful harassment or which gives rise to, or which could reasonably give rise to, an actual or perceived conflict of interest; (v) the commission by Executive of an act of fraud or dishonesty toward the Company or any subsidiary with respect to any material matter; (vi) Executive’s willful misconduct or gross negligence which demonstrably damages or injures the Company or the Company’s reputation; (vii) Executive is convicted of or pleads guilty to a felony; or (viii) the use or imparting by Executive of any confidential or proprietary information of the Company or any subsidiary in material violation of Section 6 below ; provided, that, in the case of conduct described in prong (i) or (iii) which, in the Company’s reasonable discretion, is capable of being cured, Executive shall have seven (7) days following Executive’s receipt of written notice from the Company in which to cure the condition constituting Cause.

 

5.2           Compensation upon Termination by the Company for Cause or by Executive without Good Reason .   Executive’s employment hereunder may be terminated during the Term by the Company for Cause or by Executive without Good Reason, provided that any termination of Executive’s employment by Executive without Good Reason shall be effective upon a thirty (30) day notice to the Company or such earlier date as the Company determines in its discretion and designates in writing.  Without limiting Executive’s right to challenge the Company’s assertion of Cause or the Company’s right to challenge Executive’s assertion of Good Reason, a termination of Executive’s employment by the Company for Cause or by Executive without Good Reason shall not constitute a breach of this Agreement.  In the event of Executive’s termination of employment (i) by the Company for Cause or (ii) by Executive without Good Reason:

 

5


 

(a)           Executive shall be entitled to receive (i) all amounts of accrued but unpaid Base Salary through the effective date of such termination of employment; (ii) reimbursement for reasonable and necessary expenses incurred by Executive through the date of notice of such termination of employment, to the extent otherwise provided under Section 4.2 above; and (iii) all other vested payments and benefits to which Executive may otherwise be entitled pursuant to the terms of the applicable benefit plan or arrangement through the effective date of such termination of employment ((i), (ii) and (iii), the (“Accrued Benefits”)).  All other rights of Executive (and, except as provided in Section 5.6 below, all obligations of the Company) hereunder or otherwise in connection with Executive’s employment with the Company shall terminate effective as of the date of such termination of employment and Executive shall not be entitled to any payments or benefits not specifically described in this subsection (a) or (b) below.

 

(b)           Any portion of any restricted stock or any other cash or equity-based incentive awards as to which the restrictions have not lapsed or as to which any other conditions shall not have been satisfied prior to the date of termination of employment shall be forfeited as of such date and any portion of Executive’s stock options that have vested and become exercisable prior to the date of termination of employment shall remain exercisable for a period of ninety (90) days following the date of termination of employment (or, such later date as may be permitted by the relevant stock option or equity plan, or, if earlier, until the expiration of the respective terms of the options), whereupon all such options shall terminate; provided , however, in the event of termination of Executive’s employment by the Company for Cause, any stock options that have not been exercised prior to the date of termination of employment shall immediately terminate as of such date.

 

5.3           Compensation upon Termination of Executive’s Employment by the Company Other Than for Cause or by Executive for Good Reason .  Executive’s employment hereunder may be terminated during the Term by the Company other than for Cause or by Executive for Good Reason.  In the event that Executive’s employment hereunder is terminated by the Company other than for Cause or by Executive for Good Reason:

 

(a)           Executive shall be entitled to receive (i) the Accrued Benefits, (ii) an amount equal to two times the sum of Executive’s then Base Salary plus Annual Target Bonus as of the date of termination of employment, such amount payable in equal installments pursuant to the Company’s standard payroll procedures for management employees over a period of two years commencing on the payroll payment date for the first full payroll period following the date that the Release (as defined below) becomes irrevocable (provided, if as of the date of termination of employment the Release could become irrevocable in either of two taxable years of Executive, to the extent required to avoid the imposition of taxes and penalties under Section 409A of the Code, payments will not commence before the first day of the later such taxable year), and (iii) with respect to group health plan coverage, a lump sum payment in an amount equal to the cost for of continuation coverage pursuant to Section 4980B of the Code (“COBRA”) for Executive and her dependents to the extent covered by a Company group health plan as of the date of termination of employment, for two years following termination of employment.  Executive shall be solely responsible for any taxes imposed on Executive arising from the Company’s payment of COBRA amounts hereunder.

 

6


 

(b)           On the date that the Release becomes irrevocable, (i) stock option awards held by Executive shall vest and become immediately exercisable and (ii) restrictions with respect to any awards of restricted stock shall lapse, in each case to the extent such options would otherwise have become vested and exercisable or such restrictions would have lapsed had Executive remained in the employ of the Company for a period of two years following the date of termination of employment.  All other awards held by Executive as of the date of termination of employment shall be treated in accordance with the terms of such awards.  Such portion of Executive’s stock options (together with any portion of Executive’s stock options that have vested and become exercisable prior to the date of termination of employment) shall remain exercisable for a period of ninety (90) days following the date of termination of employment (or, such later date as may be permitted by the relevant stock option or equity plan, or, if earlier, until the expiration of the respective terms of the options), whereupon all such options shall terminate.  Any remaining portion of Executive’s stock options that have not vested (and do not vest by application of this Section 5.3(b)) as of the date of termination of employment shall terminate as of such date; and all shares of restricted stock as to which the restrictions shall not have lapsed based on the application of this Section 5.3(b) shall be forfeited as of such date.  In the event of a Change in Control (as defined in the LTIP) that occurs during the Term, the provisions of section 14 of the LTIP are incorporated herein by reference; provided, however, that, notwithstanding anything to the contrary contained in such provisions, any performance-based equity award shall be treated in accordance with the terms of the applicable award agreement, which shall be no less favorable than those provided for other senior executives of the Company generally.

 

(c)           If a termination of employment pursuant to Section 5.3 of the Agreement occurs following the start of the Company’s fiscal year, Executive shall also be entitled to receive, at the same time as is paid to other eligible participants in the bonus plan, following determination by the Compensation Committee (or the Board) of the Company’s performance under the applicable annual performance goals for the fiscal year, a pro rata annual bonus determined by multiplying the performance level achieved (relative to Executive’s Annual Target Bonus amount) by the fraction (x) the numerator of which is the number of fiscal periods (months) in which Executive is employed during the fiscal year and (y) the denominator of which is 12.  Executive shall also receive any unpaid annual bonus earned for any completed fiscal year preceding the date of termination of employment.

 

(d)           All other rights of Executive (and, except as provided in Section 5.6 below, all obligations of the Company) hereunder or otherwise in connection with Executive’s employment with the Company shall terminate effective as of the date of such termination of employment and Executive shall not be entitled to any payments or benefits not specifically described in 5.3(a) through (c).

 

Any termination of employment pursuant to this Section 5.3 shall be effective upon a thirty (30) day notice thereof or the Company may elect in its sole discretion to reduce or eliminate the notice period and pay Executive her Base Salary for some or all of the notice period in lieu of notice.  Without limiting Executive’s right to challenge the Company’s assertion of Cause or the Company’s right to challenge Executive’s assertion of Good Reason, a termination of Executive’s employment by the Company other than for Cause or by Executive for Good Reason shall not constitute a breach of this Agreement.  To be eligible for the payment, benefits and equity rights described in Section 5.3(a)(ii)-(iii), (b) and (c) above, Executive must

 

7


 

(x) execute, within forty-five (45) days after the date of termination of employment, not revoke, and abide by a release (which shall be substantially in the form attached hereto as Appendix A ) of all other claims (the “Release”), (y) cooperate with the Company in the event of litigation, and (z) fully comply with Executive’s obligations under Sections 6 and 7 below.

 

5.4           Definition of Good Reason For purposes of this Agreement, “Good Reason” shall mean the occurrence of any one of the following:

 

(a)           the assignment to Executive of any duties or responsibilities materially inconsistent with Executive’s status and positions as Chief Executive Officer of the Company, or any material adverse change in Executive’s title or reporting relationship; or

 

(b)           any decrease in Executive’s then Base Salary to which Executive has not agreed to in writing; or

 

(c)           a material breach by the Company of this Agreement;

 

provided, however, that Executive has provided written notice (which shall set forth in reasonable detail the specific conduct of the Company that constitutes Good Reason and the specific provisions of this Agreement on which Executive relies) to the Company of the existence of any condition described in any one of the subparagraphs (a), (b), or (c) within thirty (30) days of Executive’s knowledge of the initial existence of such condition, and the Company has not cured the condition within thirty (30) days of the receipt of such notice.  Any termination of employment by Executive for Good Reason pursuant to Section 5.3 must occur no later than the date that is the three (3) month anniversary of Executive’s knowledge of the initial existence of the condition giving rise to the termination right.

 

5.5           Compensation upon Termination of Executive’s Employment by Reason of Executive’s Death or Total Disability During the Term, Executive’s employment hereunder shall terminate upon Executive’s death and may be terminated by the Company on account of Executive’s Total Disability (as defined below).  In the event that Executive’s employment with the Company is terminated by reason of Executive’s death or due to involuntary termination of Executive’s employment by the Company on account of Executive’s Total Disability (as defined below), subject to the requirements of applicable law:

 

(a)           Executive or Executive’s estate, as the case may be, shall be entitled to receive (i) the Accrued Benefits, (ii) any other benefits payable under the then current disability and/or death benefit plans, as applicable, in which Executive is a participant and (iii) with respect to group health plan coverage, a lump sum payment in an amount equal to the cost of continuation coverage pursuant to COBRA for Executive and her dependents to the extent covered by a Company group health plan as of the date of termination of employment, for a period of two years following the date of termination of employment.  Executive or Executive’s estate shall be solely responsible for any taxes imposed on Executive arising from the Company’s payment of COBRA amounts hereunder.  Executive or Executive’s estate shall also be entitled to receive, at the same time as is paid to other eligible participants in the bonus plan, following determination by the Compensation Committee (or the Board) of the Company’s performance under the applicable annual performance goals for the fiscal year, a pro rata annual

 

8


 

bonus determined by multiplying the performance level achieved  (relative to Executive’s Annual Target Bonus amount) by the fraction (x) the numerator of which is the number of fiscal periods (months) in which Executive is employed during the fiscal year and (y) the denominator of which is 12.  Executive or Executive’ estate shall also be entitled to any unpaid annual bonus earned for any completed fiscal year preceding the date of termination of employment.

 

(b)           (i) Stock option awards held by Executive shall vest and become immediately exercisable and (ii) restrictions with respect to any awards of restricted stock shall lapse, in each case to the extent such options would otherwise have become vested and exercisable or such restrictions would have lapsed had Executive remained in the employ of the Company for a period of two years following the date of termination of employment pursuant to this Section 5.5.  All other awards held by Executive as of the date of termination of employment shall be treated in accordance with the terms of such awards.  Such portion of Executive’s stock options (together with any portion of Executive’s stock options that have vested and become exercisable prior to the date of termination of employment) shall remain exercisable for a period of ninety (90) days following the date of termination of employment (or, such later date as may be permitted by the relevant stock option or equity plan, or, if earlier, until the expiration of the respective terms of the options), whereupon all such options shall terminate.  Any remaining portion of Executive’s stock options that have not vested (and do not vest by application of this Section 5.5(b)) as of the date of termination of employment shall terminate as of such date; and all shares of restricted stock as to which the restrictions shall not have lapsed based on the application of this Section 5.5(b) shall be forfeited as of such date.

 

(c)           All other rights of Executive (and, except as provided in Section 5.6 below, all obligations of the Company) hereunder or otherwise in connection with Executive’s employment with the Company shall terminate effective as of the date of such termination of employment and Executive shall not be entitled to any payments or benefits not specifically described in Section 5.5(a) through (c).

 

“Total Disability” shall mean any physical or mental disability that prevents Executive from (a)(i) performing one or more of the essential functions of her position for a period of not less than ninety (90) days in any twelve (12) month period and (ii) which is expected to be of permanent or indeterminate duration but expected to last at least twelve (12) continuous months or result in death of Executive as determined (y) by a physician selected by the Company or its insurer or (z) pursuant to the Company’s benefit programs; or (b) reporting to work for ninety (90) or more consecutive business days or as a result of which Executive is unable to engage in any substantial activity.

 

5.6           Change in Control Best Payments Determination .   Any other provision of this Agreement to the contrary notwithstanding, if any portion of any payment or benefit under this Agreement either individually or in conjunction with any payment or benefit under any other plan, agreement or arrangement (all such payments and benefits, the “Total Payments”) would constitute an “excess parachute payment” within the meaning of Internal Revenue Code Section 280G, that is subject to the tax imposed by Section 4999 of such Code, then the Total Payments to be made to Executive shall be reduced, but only to the extent that Executive would retain a greater amount on an after-tax basis than he would retain absent such reduction, such that the value of the Total Payments that Executive is entitled to receive shall be $1 less than the

 

9


 

maximum amount which the Employee may receive without becoming subject to the excise tax under Section 4999 of the Code.  For purposes of this Section 5.6, the determination of whichever amount is greater on an after-tax basis shall be (i) based on maximum federal, state and local income and employment tax rates and the tax that would be imposed on Executive pursuant to Section 4999 and (ii) made at the Company’s expense by consultants selected by the Company prior to the date of the change in control, which determination shall be binding on both Executive and the Company.  Any such reduction as may apply under this Section 5.6 shall be applied in the following order: (i) payments that are payable in cash the full amount of which are treated as parachute payments under Treasury Regulation Section 1.280G-1, Q&A 24(a) shall be reduced (if necessary, to zero), with amounts that are payable last reduced first; (ii) payments and benefits due in respect of any equity the full amount of which are treated as parachute payments under Treasury Regulation Section 1.280G-1, Q&A 24(a), with the highest values reduced first (as such values are determined under Treasury Regulation Section 1.280G-1, Q&A 24), shall next be reduced; (iii) payments that are payable in cash that are valued at less than full value under Treasury Regulation Section 1.280G-1, Q&A 24, with amounts that are payable last reduced first, shall next be reduced; (iv) payments and benefits due in respect of any equity valued at less than full value under Treasury Regulation Section 1.280G-1, Q&A 24, with the highest values reduced first (as such values are determined under Treasury Regulation Section 1.280G-1, Q&A 24), shall next be reduced; and (v) all other non-cash benefits not otherwise described in clauses (ii) or (iv) shall be next reduced pro-rata.

 

5.7           No Other Severance or Termination Benefits Except as expressly set forth herein, Executive shall not be entitled to any contractual severance or other benefits upon termination of employment with the Company under any circumstances and for any or no reason, including, but not limited to any severance pay under any Company severance plan, policy or practice.

 

6.              Protection of Confidential Information .

 

Executive acknowledges that during the course of her employment with the Company, its subsidiaries, affiliates and strategic partners, she will be exposed to documents and other information regarding the confidential affairs of the Company, its subsidiaries, affiliates and strategic partners, including without limitation, information about their past, present and future financial condition, pricing strategy, prices, suppliers, cost information, business and marketing plans, the markets for their products, key personnel, past, present or future actual or threatened litigation, trade secrets, and other intellectual property, current and prospective customer lists, operational methods, acquisition plans, prospects, plans for future development and other business affairs and information about the Company and its subsidiaries, affiliates and strategic partners not readily available to the public (the “Confidential Information”).  Executive further acknowledges that the services to be performed under this Agreement are of a special, unique, unusual, extraordinary and intellectual character.  In recognition of the foregoing, Executive covenants and agrees as follows:

 

6.1           No Disclosure or Use of Confidential Information Subject to Section 6.3, below, at no time shall Executive ever divulge, disclose, or otherwise use any Confidential Information (other than as necessary to perform her duties under this Agreement and in furtherance of the Company’s best interests), unless and until such information is readily

 

10


 

available in the public domain by reason other than Executive’s disclosure or use thereof in violation of the first clause of this Section 6.1.  Executive acknowledges that Company is the owner of, and that Executive has no rights to, any trade secrets, patents, copyrights, trademarks, know-how or similar rights of any type, including any modifications or improvements to any work or other property developed, created or worked on by Executive during the Term of this Agreement.

 

6.2                                Return of Company Property, Records and Files Upon the termination of Executive’s employment at any time and for any reason, or at any other time the Board may so direct, Executive shall promptly deliver to the Company’s offices in Harrisburg, Pennsylvania all of the property and equipment of the Company, its subsidiaries, affiliates and strategic partners (including any cell phones, pagers, credit cards, personal computers, etc.) and any and all documents, records, and files, including any notes, memoranda, customer lists, reports or any and all other documents, including any copies thereof, whether in hard copy form or on a computer disk or hard drive, which relate to the Company, its subsidiaries, affiliates, strategic partners, successors or assigns, and/or their respective past and present officers, directors, employees or consultants (collectively, the “Company Property, Records and Files”); it being expressly understood that, upon termination of Executive’s employment at any time and for any reason, Executive shall not be authorized to retain any of the Company Property, Records and Files, any copies thereof or excerpts therefrom.  Executive further agrees that Executive shall permanently delete any Company Property, Records and Files which cannot be returned to the Company in their entirety (including any such Company Property, Records or Files on a cloud storage system).

 

6.3                                Permitted Disclosures .   Pursuant to 18 U.S.C. § 1833(b), Executive understands that Executive will not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret of the Company that (a) is made (i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to Executive’s attorney and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (b) is made in a complaint or other document that is filed under seal in a lawsuit or other proceeding.  Executive understands that if Executive files a lawsuit for retaliation by the Company for reporting a suspected violation of law, Executive may disclose the trade secret to Executive’s attorney and use the trade secret information in the court proceeding if Executive (x) files any document containing the trade secret under seal, and (y) does not disclose the trade secret, except pursuant to court order.  Nothing in this Agreement, or any other agreement that Executive has with the Company, is intended to conflict with 18 U.S.C. § 1833(b) or create liability for disclosures of trade secrets that are expressly allowed by such section.  Further, nothing in this Agreement or any other agreement that Executive has with the Company shall prohibit or restrict Executive from (A) making any voluntary disclosure of information or documents concerning possible violations of law to any governmental agency or legislative body, or any self-regulatory organization, in each case, without advance notice to the Company; or (B) responding to a valid subpoena, court order or similar legal process; provided, however, that prior to making any such disclosure pursuant to this Section 6.3(B), Executive shall provide the Company with written notice of the subpoena, court order or similar legal process sufficiently in advance of such disclosure to afford the Company a reasonable opportunity to challenge the subpoena, court order or similar legal process.

 

11


 

7.                                       Noncompetition and Other Matters .

 

7.1                                Noncompetition .  During Executive’s employment with the Company and during the twelve (12) month period following the termination of Executive’s employment with the Company for any reason (the “Restricted Period”), Executive will not, directly or indirectly, engage in Competition with the Company or any of its subsidiaries in the Restricted Area (as defined below).  “Competition” shall mean engaging in any activity for a Competitor of the Company or any of its subsidiaries, with or without compensation, whether as a principal, agent, partner, officer, director, employee, advisor, independent contractor, investor, consultant or stockholder (except as a less than five percent (5%) shareholder of a publicly traded company) or otherwise.  A “Competitor” shall mean any person, corporation or other entity and its parents, subsidiaries, affiliates and assigns, (collectively, a “Person”) that engages, or is preparing to engage, in the same or substantially similar business as one or more business units of the Company or its subsidiaries.  As of the Commencement Date, it is understood that the Company’s business units include:  (1) pharmacy benefits management (“PBM”), including the administration of pharmacy benefits for businesses, government agencies or health plans; mail order pharmacy; specialty pharmacy and Medicare Part D services; (2) the sale of prescription drugs either at retail or over the internet; and (3) retail health care (“RediClinic”).  It is understood and agreed that PBM competitors include, but are not limited to, CVS Health, Express Scripts and Optum, as well as health plans or insurers that provide PBM services.  It is also understood and agreed that retail pharmacy competitors include any individual or entity that sells or has imminent plans to sell prescription drugs, including but not limited to, drugstore companies such as Walgreens Boots Alliance and CVS Health; mass merchants such as Wal-Mart Stores, Inc. and Target Corp.; and food/drug combinations such as Kroger Co., Albertsons LLC and Ahold USA.  It is understood and agreed that RediClinic competitors include, but are not limited to, Walgreen’s Take Care Clinics, CVS Health’s Minute Clinics and The Little Clinic. During Executive’s employment by the Company or one of its subsidiaries and during the Restricted Period, Executive will not directly or indirectly, engage in any activity that involves providing audit review or other consulting or advisory services with respect to any relationship between the Company and any third party.  The “Restricted Area” means those states within the United States in which the Company, including its subsidiaries, conducts its business, including the District of Columbia and Puerto Rico.

 

7.2                                Noninterference .   During the Restricted Period, Executive shall not, directly or indirectly, solicit, induce, or attempt to solicit or induce any officer, director, employee, agent or consultant of the Company or any of its subsidiaries, affiliates, strategic partners, successors or assigns to terminate his, her or its employment or other relationship with the Company or its subsidiaries, affiliates, strategic partners, successors or assigns for the purpose of associating with any Competitor of the Company or its subsidiaries, affiliates, strategic partners, successors or assigns, or otherwise encourage any such person or entity to leave or sever his, her or its employment or other relationship with the Company or its subsidiaries, affiliates, strategic partners, successors or assigns for any other reason.

 

7.3                                Nonsolicitation During the Restricted Period, Executive shall not, directly or indirectly, solicit, induce, or attempt to solicit or induce any customers, clients, vendors, suppliers or consultants then under contract to the Company or its subsidiaries, affiliates, strategic partners, successors or assigns, to terminate, limit or otherwise modify his, her or its

 

12


 

relationship with the Company or its subsidiaries, affiliates, strategic partners, successors or assigns, for the purpose of associating with any Competitor of the Company or its subsidiaries, affiliates, strategic partners, successors or assigns, or otherwise encourage such customers, clients, vendors, suppliers or consultants then under contract to terminate his, her or its relationship with the Company or its subsidiaries, affiliates, strategic partners, successors or assigns for any reason.  During the Restricted Period, Executive shall not hire, either directly or through any employee, agent or representative, any person known by Executive to be (or to have been) a field and corporate management employee of the Company or any subsidiary or any such person who was employed by the Company or any subsidiary within 180 days of such hiring.

 

8.                                       Rights and Remedies upon Breach .  If Executive breaches, or threatens to commit a breach of, any of the provisions of Sections 6 or 7 above (the “Restrictive Covenants”), the Company and its subsidiaries, affiliates, strategic partners, successors or assigns shall have the following rights and remedies, each of which shall be independent of the others and severally enforceable, and each of which shall be in addition to, and not in lieu of, any other rights or remedies available to the Company or its subsidiaries, affiliates, strategic partners, successors or assigns at law or in equity:

 

8.1                                Specific Performance .   The right and remedy to have the Restrictive Covenants specifically enforced by any court of competent jurisdiction by injunctive decree or otherwise (without the necessity of posting a bond), it being agreed that any breach or threatened breach of the Restrictive Covenants would cause irreparable injury to the Company or its subsidiaries, affiliates, strategic partners, successors or assigns and that money damages would not provide an adequate remedy to the Company or its subsidiaries, affiliates, strategic partners, successors or assigns.

 

8.2                                Accounting The right and remedy to require Executive to account for and pay over to the Company or its subsidiaries, affiliates, strategic partners, successors or assigns, as the case may be, all compensation, profits, monies, accruals, increments or other benefits derived or received by Executive as a result of any transaction or activity constituting a breach of any of the Restrictive Covenants.

 

8.3                                Cessation and Recoupment of Payments .   In the event that Executive is receiving payments and benefits pursuant to Section 5.3, above, the right and remedy to immediately cease making and providing Executive any future payments and benefits (except for the Accrued Benefits) and be promptly reimbursed by Executive for any payments and benefits (except for the Accrued Benefits) paid or provided to Executive pursuant to Section 5.3 during the period of such breach by Executive.

 

8.4                                Extension of Restriction in the Event of Breach The right and remedy to extend the length of time of the Restricted Period for a period of time equal to the period of time during which Executive was or is in breach of such provision.

 

13


 

9.                                       Enforceability in Jurisdictions.   Executive intends to and hereby confers jurisdiction to specifically enforce the Restrictive Covenants by issuing an injunction in aid of arbitration upon the courts of any jurisdiction within the Restricted Area.  If the courts of any one or more of such jurisdictions hold the Restrictive Covenants unenforceable by reason of the breadth of such scope or otherwise, it is the intention of Executive that such determination not bar or in any way affect the right of the Company or its subsidiaries, affiliates, strategic partners, successors or assigns to the relief provided herein in the courts of any other jurisdiction within the geographic scope of such covenants, as to breaches of such covenants in such other respective jurisdictions, such covenants as they relate to each jurisdiction being, for this purpose, severable into diverse and independent covenants.

 

10.                                Reasonableness; Severability; Modification Executive acknowledges and agrees that the Restrictive Covenants are reasonable and necessary given Executive’s position of trust and confidence within the Company and Executive’s significant access to confidential information.  Executive further agrees that the Restrictive Covenants are valid in geographic and temporal scope and in all other respects.  If any provision of the Restrictive Covenants is held to be excessively broad as to duration, activity or subject, it is the desire of the Company and Executive that such provisions be construed by limiting and reducing them so as to be enforceable to the maximum extent allowed by applicable law and then fully enforced as so modified.  In the event that any one or more of the provisions shall be held to be invalid, illegal or unenforceable, it is the desire of the Company and Executive that the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby.  any of the Restrictive Covenants, or any part thereof, is invalid or unenforceable, the remainder of the Restrictive Covenants shall not thereby be affected and shall be given full force and effect without regard to the invalid portions.

 

11.                                No Violation of Third-Party Rights; Other Representations .

 

(a)                                  Executive represents, warrants and covenants that he:

 

(i)                                      will not, in the course of employment, infringe upon or violate any proprietary rights of any third party (including, without limitation, any third party confidential relationships, patents, copyrights, mask works, trade secrets, or other proprietary rights);

 

(ii)                                   is not a party to any conflicting agreements with third parties, which will prevent him from fulfilling the terms of employment and the obligations of this Agreement;

 

(iii)                                does not have in her possession any confidential or proprietary information or documents belonging to others and will not disclose to the Company, use, or induce the Company to use, any confidential or proprietary information or documents of others;

 

(iv)                               agrees to respect any and all valid obligations which he may now have to prior employers or to others relating to confidential information, inventions, discoveries or other intellectual property which are the property of those prior employers

 

14


 

or others, as the case may be; and

 

(v)                                  is not currently a defendant in any pending or threatened litigation or arbitration, or, to Executive’s knowledge, subject to an investigation, including with any current or former employer or business associate, in each case, regarding allegations relating to sexual or other types of harassment or abusive behavior.

 

(b)                                  Executive has supplied to the Company a copy of each written agreement with any of Executive’s prior employers, as well as any other agreements to which Executive is subject, which includes any obligation of confidentiality, assignment of intellectual property, nonsolicitation or noncompetition.  Executive has listed each of such agreements in Appendix B .

 

(c)                                   Executive agrees to indemnify and hold the Company harmless from any loss, claim, damage, cost or expense of any kind (including without limitation, reasonable attorney fees) to which the Company may be subjected by virtue of a breach by Executive of the foregoing representations, warranties, and covenants.

 

12.                                Arbitration .  Except as necessary for Executive or the Company and its subsidiaries, affiliates, successors or assigns or Executive to specifically enforce, or enjoin a breach of, this Agreement (to the extent such remedies are otherwise available), including, without limitation, pursuant to Section 8.1, above, the Parties agree that any and all disputes that may arise in connection with, arising out of or relating to this Agreement, or any dispute that relates in any way, in whole or in part, to Executive’s employment with the Company or any subsidiary or affiliate, the termination of that employment or any other dispute by and between the Parties or their subsidiaries, affiliates, successors or assigns, shall be submitted to final and binding arbitration in Harrisburg, Pennsylvania according to the National Employment Dispute Resolution Rules and procedures of the American Arbitration Association at the time in effect.  This arbitration obligation extends, to the fullest extent permitted by law, to any and all claims that may arise by and between the Parties or their subsidiaries, affiliates, strategic partners, successors or assigns, and expressly extends to, without limitation, claims or causes of action for wrongful employment termination, impairment of ability to compete in the open labor market, breach of an express or implied contract, breach of the covenant of good faith and fair dealing, breach of fiduciary duty, fraud, misrepresentation, defamation, slander, infliction of emotional distress, disability, loss of future earnings, and claims under the Pennsylvania Constitution, the United States Constitution, and applicable state and federal fair employment laws, federal and state equal employment opportunity laws, and federal and state labor statutes and regulations, including, but not limited to, the Civil Rights Act of 1964, as amended, the Fair Labor Standards Act, as amended, the Americans With Disabilities Act of 1990, as amended, the Rehabilitation Act of 1973, as amended, the Employee Retirement Income Security Act of 1974, as amended, the Age Discrimination in Employment Act of 1967, as amended, and any other state or federal law.  The Company shall pay all fees and expenses of the arbitrator (other than a filing fee that Executive would have paid to commence litigation in a state court located in Harrisburg, Pennsylvania, in the event that Executive commences such arbitration hereunder).  Executive understands that by entering into this Agreement, Executive is waiving Executive’s rights to have a court determine Executive’s rights, including under federal, state or local statutes prohibiting employment discrimination, including sexual harassment and discrimination on the basis of age, race, color, religion, national origin, disability, veteran status or any other factor

 

15


 

prohibited by governing law.  Executive further understands that there is no intent herein to interfere with the Equal Employment Opportunity Commission’s right to enforce the laws it oversees or your right to file an administrative charge of employment discrimination or a similar state or local administrative agency.

 

13.                                Assignment .

 

(a)                                  Neither this Agreement, nor any of Executive’s rights or obligations hereunder, may be assigned or otherwise subject to hypothecation by Executive.  Any attempt by Executive to anticipate, alienate, assign, sell, transfer, pledge, encumber or charge the same shall be void.  In the event of Executive’s death, the Company shall pay to Executive’s estate all unpaid amounts that were payable to Executive immediately prior to her death.

 

(b)                                  The Company may freely assign its rights and obligations hereunder, and Executive hereby consents to any such assignment, in whole or in part, to any of the Company’s subsidiaries, affiliates, or parent corporations. The Company shall assign this Agreement to any successor or assign in connection with the sale of all or substantially all of the Company’s assets or stock, or in connection with any merger in which the Company is not the survivor, or any acquisition and/or reorganization involving the Company.

 

14.                                Notices .

 

All notices and other communications under this Agreement shall be in writing and shall be: (i) in writing; (ii) delivered personally, by fax, by electronic mail, by courier service, or by certified or registered mail, first class postage prepaid and return receipt requested; (iv) deemed to have been received on the date of delivery or, if sent by certified or registered mail, on the third (3 rd ) business day after the mailing thereof, or if sent by fax, twenty-four (24) hours after transmission of a fax; and (iv) addressed as follows (or to such other address as the Party entitled to notice shall hereafter designate in accordance with the terms hereof):

 

If to the Company:

Rite Aid Corporation
30 Hunter Lane
Camp Hill, Pennsylvania 17011
Attention: General Counsel
Fax: (717) 760-7867
Email: jcomitale@riteaid.com

 

 

If to Executive:

Heyward Donigan, at the address noted on Appendix C.

 

Any Party may change such Party’s address for notices by notice duly given pursuant hereto.

 

15.                                General .

 

15.1                         No Offset or Mitigation The Company’s obligation to make the payments provided for in, and otherwise to perform its obligations under this Agreement shall not be affected by any set-off, counterclaim, recoupment, defense or other claim, right or action that the Company may have against Executive or others whether in respect of claims made under this Agreement or otherwise.  In no event shall Executive be obligated to seek other employment or

 

16


 

take any other action by way of mitigation of the amounts, benefits and other compensation payable or otherwise provided to Executive under any of the provisions of this Agreement, and such amounts shall not be reduced, regardless of whether Executive obtains other employment.

 

15.2                         Negotiation Expenses The Company shall pay Executive’s reasonable professional fees incurred to negotiate and prepare this Agreement and all related agreements up to an aggregate amount of $7,500. The provisions of Section 16.3 shall apply to all reimbursements made under this Section 15.2.

 

15.3                         Governing Law .  This Agreement is executed in Pennsylvania and shall be governed by and construed and enforced in accordance with the laws of the Commonwealth of Pennsylvania without giving effect to conflicts of laws principles thereof which might refer such interpretations to the laws of a different state or jurisdiction.

 

15.4                         Entire Agreement This Agreement sets forth the entire understanding of the Parties relating to Executive’s employment with the Company and cancels and supersedes all agreements, arrangements and understandings relating thereto made prior to the date hereof, written or oral, between Executive and the Company and/or any subsidiary or affiliate.

 

15.5                         Amendments: Waivers This Agreement may be amended, modified, superseded, canceled, renewed or extended, and the terms or covenants hereof may be waived, only by a written instrument executed by the Parties, or in the case of a waiver, by the Party waiving compliance. The failure of any Party at any time or times to require performance of any provision hereof shall in no manner affect the right of such Party at a later time to enforce the same.  No waiver by any Party of the breach of any term or covenant contained in this Agreement, whether by conduct or otherwise, in any one or more instances, shall be deemed to be, or construed as, a further or continuing waiver of any such breach, or a waiver of the breach of any other term or covenant contained in this Agreement.

 

15.6                         Conflict with Other Agreements Executive represents and warrants that neither her execution of this Agreement nor the full and complete performance of her obligations hereunder will violate or conflict in any respect with any written or oral agreement or understanding with any person or entity.

 

15.7                         Successors and Assigns This Agreement shall inure to the benefit of and shall be binding upon the Company (and its successors and assigns) and Executive and her heirs, executors and personal representatives.

 

15.8                         Withholding Notwithstanding any other provision of this Agreement, the Company may withhold from amounts payable under this Agreement all federal, state, local, payroll and foreign taxes that are required to be withheld by applicable laws or regulations.

 

15.9                         General Severability The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement.  If any provision of this Agreement shall be held invalid or unenforceable in part, the remaining portion of such provision, together with all other provisions of this Agreement, shall remain valid and enforceable and continue in full force and effect to the fullest extent consistent with law.

 

17


 

15.10                  Survival . In the event of any termination of Executive’s employment during the Term, or upon or after expiration of the Term, Executive and the Company nevertheless shall continue to be bound by the terms and conditions set forth in Section 4.6 and Sections 6 through 10 above, which shall survive the expiration of the Term.

 

15.11                  Captions The section headings contained herein are for reference purposes only and shall not in any way affect the meaning or interpretation of this Agreement.

 

15.12                  Counterparts ; Electronic Signatures This Agreement may be executed by the Parties hereto in separate counterparts; each of which when so executed and delivered shall be an original but all such counterparts together shall constitute one and the same instrument.  Each party agrees that electronic signatures, whether digital or encrypted, of either party to this Agreement, are intended to authenticate this writing and to have the same force and effect as manual signatures.

 

16.                                Compliance with Code Section 409A .

 

16.1                         Interpretation .  The intent of the Parties is that payments and benefits under this Agreement comply with Section 409A of the Code (“409A”), to the extent subject thereto, and accordingly, to the maximum extent permitted, this Agreement shall be interpreted and administered to be in compliance therewith.  Notwithstanding anything contained herein to the contrary, Executive shall not be considered to have terminated employment with the Company for purposes of any payments under this Agreement which are subject to 409A until Executive has incurred a “separation from service” from the Company within the meaning of 409A.

 

16.2                         Payment of Benefits To the extent necessary to avoid adverse tax consequences, and except as described below, any payment to which Executive becomes entitled under the Agreement, or any arrangement or plan referenced in this Agreement, that constitutes “deferred compensation” under 409A, and is (a) payable upon Executive’s termination of employment; (b) at a time when Executive is a “specified employee” as defined by 409A shall not be made until the first payroll date after the earliest of:  (1) the expiration of the six (6) month period (the “Deferral Period”) measured from the date of Executive’s “separation from service” within the meaning of such term under 409A; or (2) the date of Executive’s death.

 

On the first payroll date after the expiration of the Deferral Period, all payments that would have been made during the Deferral Period (whether in a single lump sum or in installments) shall be paid as a single lump sum to Executive or, if applicable, her beneficiary.  This section shall not apply to any payment which meets the short term deferral exception to 409A or constitutes “separation pay” as described in Treasury Regulation Section 409A-1(b)(9) (in general, payments (i) that are made on an involuntary separation from service which (ii) do not exceed the lesser of two (2) times (x) Executive’s annualized compensation for the taxable year preceding the year in which the separation from service occurs or (y) the Code Section 401(a)(17) limit on compensation for the year in which separation from service occurs and (iii) are paid in total by the end of the second calendar year following the calendar year in which the separation from service occurs).

 

18


 

The Company shall pay to Executive the Accrued Benefits, within ten (10) days after the Date of Termination.  Notwithstanding the foregoing, if Executive is a “specified employee”, as defined by 409A, and payment of the Accrued Benefits is required to be delayed under 409A, the Company shall pay to Executive the Accrued Benefits on the first payroll date after the six (6) month anniversary of the Date of Termination.

 

For purposes of 409A, each payment and each installment described in this Agreement shall be considered a separate payment from each other payment or installment and to the extent required by 409A, a payment due upon termination of employment will only be paid upon Executive’s separation from service within the meaning of such term under 409A.

 

16.3                         Reimbursements .   To the extent required by 409A, with regard to any provision that provides for the reimbursement of costs and expenses, or for the provision of in-kind benefits:  (i) the right to such reimbursement or in-kind benefit shall not be subject to liquidation or exchange for another benefit; (ii) the amount of expenses or in-kind benefits available or paid in one (1) year shall not affect the amount available or paid in any subsequent year; and (iii) such payments shall be made on or before the last day of Executive’s taxable year in which the expense occurred.

 

19


 

IN WITNESS WHEREOF, Executive and the Company have executed this Agreement as of the date first written above.

 

 

RITE AID CORPORATION

 

 

 

/s/ James J. Comitale

 

By: James J. Comitale

 

Its: SVP, General Counsel and Secretary

 

 

 

EXECUTIVE

 

 

 

/s/ Heyward Donigan

 

Heyward Donigan

 


 

Appendix A to Employment Agreement

[Form of Severance Agreement and Release]

 

This Agreement (this “ Agreement ”) confirms the terms of the separation of employment of [NAME] (“ you ”) from Rite Aid Corporation (the “ Company ,” and together with you, the “ Parties ”).  Capitalized terms not otherwise defined herein will have the meanings attributed to them in your employment agreement with the Company, effective as of [DATE] (the “ Employment Agreement ”).

 

1.                                       Separation Date . Your last day of employment with the Company will be [DATE] (the “ Separation Date ”) and as of such date you shall cease to be employed by the Company in any capacity and you will automatically resign from all positions you then hold with the Company and its subsidiaries including as a member of the Board of Directors of the Company (as well as of the Board of Directors of any of the Company’s subsidiaries), to the extent applicable.  You agree to execute any additional documents required or requested by the Company to effectuate your resignations from such positions.  You agree that, following the Separation Date, you will not represent yourself to be associated in any ongoing capacity with the Company or any of its subsidiaries or affiliates.

 

2.                                       Accrued Benefits; Severance .

 

(a)                                  Whether or not this Agreement becomes effective pursuant to its terms, the Company will pay you the amount of accrued but unpaid base salary through the Separation Date and reimburse you for reasonable expenses incurred by you in furtherance of your duties through the date of notice of your termination of employment in accordance with Company policies, less all applicable withholdings and deductions.(1)

 

(b)                                  Provided that this Agreement becomes effective pursuant to its terms and you remain in compliance with this Agreement, and with the Restrictive Covenants, at all times, the Company will pay and provide you with the severance benefits, at the time and in the form, set forth in Section 5.3 of the Employment Agreement, less all applicable withholdings and deductions.

 

3.                                       Release .

 

(a)                                  You hereby release, discharge and forever acquit the Company, and its affiliates and subsidiaries and each of their respective past, present and future stockholders, members, partners,  directors, managers, employees, agents, attorneys, heirs, legal representatives, and each of the successors and assigns of the foregoing, in their personal and representative capacities (individually, “ Company Party ,” and collectively, the “ Company Parties ”), from liability for, and hereby waive, any and all claims, charges, liabilities, causes of action, rights, complaints, sums of money, suits, debts, covenants, contracts, agreements, promises, benefits, obligations, damages, demands or liabilities of every nature, kind and

 


(1)          In addition, the actual Release will include a specific list of vested benefits under employee benefit plans to be excluded from the Release requirement.

 

21


 

description, in law, equity or otherwise, whether known or unknown , suspected or unsuspected (collectively, “ Claims ”) which you or your heirs, executors, administrators, spouse, relatives, successors or assigns ever had, now have or may hereafter claim to have by reason of any matter, cause or thing whatsoever: (i) arising from the beginning of time through the date upon which you sign this Agreement including, but not limited to (A) any such Claims relating in any way to your employment relationship with the Company or any other Company Parties, and (B) any such Claims arising under any federal, state, local or foreign statute or regulation, including, without limitation, the Age Discrimination in Employment Act of 1967, as amended by the Older Workers Benefit Protection Act (the “ ADEA ”), Title VII of the Civil Rights Act of 1964, the Americans with Disabilities Act of 1990, the Employee Retirement Income Security Act of 1974, the Pennsylvania Human Relations Act, the Pennsylvania Equal Pay Law and any other federal, state, local or foreign law (statutory, regulatory or otherwise) that may be legally waived and released; (ii) relating to wrongful employment termination; or (iii) arising under or relating to any policy, agreement, understanding or promise, written or oral, formal or informal, between the Company or any of the other Company Parties and you, including, without limitation, the Employment Agreement and any incentive compensation plan or equity plan with any Company Party.  Notwithstanding the above, this release does not extend to (I) claims for Accrued Benefits; (II) claims for worker’s compensation benefits or for an occupational disease; (III) any whistleblower claims arising under the Sarbanes-Oxley Act or Dodd-Frank Wall Street Reform and Consumer Protection Act; (IV) claims to require the Company to honor its commitments set forth in this Agreement; (V) claims to interpret or to determine the scope, meaning or effect of this Agreement; (VII) claims for indemnification and officers and directors liability insurance coverage under the Employment Agreement, the Company’s charter, by-laws or applicable law, as applicable; and/or (VIII) claims that cannot be waived as a matter of law pursuant to federal, state, or local law (collectively, clauses (I) through (VIII) are the “ Excluded Claims ”).

 

(b)                                  You further acknowledge and agree that, except with respect to the Accrued Benefits, the Company Parties have fully satisfied any and all obligations whatsoever owed to you arising out of your employment with the Company or any other Company Party, and that no further payments or benefits are owed to you by the Company or any other Company Party.

 

4.                                       Attorney Consultation; Voluntary Agreement .

 

(a)                                  You acknowledge that (i) the Company has advised you to consult with an attorney of your own choosing before signing this Agreement, (ii) you have been given the opportunity to seek the advice of counsel, (iii) you have carefully read and fully understand all of the provisions of this Agreement, including the release in Section 3 (the “ Release ”), (iv) the Release specifically applies to any rights or claims you may have against the Company Parties pursuant to the ADEA, (v) you are entering into this Agreement knowingly, freely and voluntarily in exchange for good and valuable consideration to which you are not otherwise entitled and (vi) you have the full power, capacity and authority to enter into this Agreement.

 

5.                                       Review and Revocation Period .

 

(a)                                  You have forty-five (45) days following your receipt of this Agreement (the “ Consideration Period ”) to review its terms, including the Release, and to reflect

 

22


 

upon them and consider whether you want to sign it, although you may sign it sooner; provided , however , that you may not sign this Agreement prior to the Separation Date.  You acknowledge and agree that changes to this Agreement, whether material or immaterial, do not restart the running of the Consideration Period.  You understand and agree that you may consent to this Agreement, including the Release, by signing and returning this Agreement within the applicable time frame to General Counsel, Rite Aid Corporation, 30 Hunter Lane, Camp Hill, PA 17011 or by e-mail at jcomitale@riteaid.com.

 

(b)                                  You may revoke your consent to the Release within the seven day period beginning on the date you execute this Agreement (such seven day period being referred to herein as the “ Release Revocation Period ”). To be effective, such revocation must be in writing signed by you and delivered to the Company at the above address before 11:59 p.m., Eastern Standard time, on the last day of the Release Revocation Period.

 

(c)                                   In the event of such revocation by you, the Release shall be of no force or effect, and you will not have any rights and the Company will not have any obligations under Section 2(b) of this Agreement.  Provided that you do not revoke your consent to the Release within the Release Revocation Period, the Release shall become effective on the eighth (8th) calendar day after the date upon which you execute this Agreement (the “ Release Effective Date ”).

 

6.                                       Restrictive Covenants .  You acknowledge and agree that the Restrictive Covenants, and any other written restrictive covenants and confidentiality agreements in effect with the Company, are incorporated herein by reference and fully made a part hereof for all purposes and remain in full force and effect.

 

7.                                       Cooperation .  You agree that, at mutually agreeable times, you will meet with representatives of the Company, or its respective parent or subsidiary company representatives and provide any information you acquired during the course of your employment relating in any way to any legal disputes involving the Company.  You further agree that you will cooperate fully with the Company relating to any such litigation matter or other legal proceeding in which you were involved or on which you have knowledge by virtue of your employment with the Company, including any existing or future litigation or other legal proceeding involving the Company, whether administrative, civil or criminal in nature in which and to the extent the Company deems your cooperation necessary.  You will be entitled to reimbursement by the Company of reasonable costs and expenses incurred by you in connection with complying with your obligations under this Section 7.

 

8.                                       Non-Disparagement . You agree that you will not make any negative comments or disparaging remarks, in writing, orally or electronically (“ Disparaging Remarks ”), about the Company or any of the other Company Parties and their respective products and services.  The Company agrees to instruct members of its senior management team not to, for as long as such individuals remain affiliated with the Company, make any Disparaging Remarks about you; provided , however , that nothing in this Section 8 shall prohibit you from (a) making truthful and accurate statements or disclosures that are required by applicable law or legal process; (b) making any voluntary disclosure of information or documents concerning possible violations of law to any governmental agency or legislative body, or any self-regulatory

 

23


 

organization; or (c) exercising protected rights to the extent that such rights, by law, cannot be waived by agreement.

 

9.                                       No Admission .  Nothing herein will be deemed to constitute an admission of wrongdoing by you or any of the Company Parties.  Neither this Agreement nor any of its terms may be used as an admission or introduced as evidence as to any issue of law or fact in any proceeding, suit or action, other than an action to enforce this Agreement.

 

10.                                Counterparts .  This Agreement may be executed in counterparts, and each counterpart, when so executed and delivered, will be deemed to be an original and both counterparts, taken together, will constitute one and the same Agreement.  A faxed or .pdf-ed signature will operate the same as an original signature.

 

11.                                Successors and Assigns .  This Agreement will inure to the benefit of and be binding upon the Company and any successor organization which shall succeed to the Company by acquisition, merger, consolidation or operation of law, or by acquisition of assets of the Company and any assigns.  You may not assign this Agreement, provided that in the event of your death prior to receiving all of the payments provided by Section 2 of this Agreement, any remaining payments will be made to your estate.

 

12.                                Severability; Blue-Penciling .  The provisions of this Agreement are severable and the invalidity of any one or more provisions will not affect the validity of any other provision.  In the event that a court of competent jurisdiction shall determine that any provision of this Agreement or the application thereof is unenforceable in whole or in part because of the scope thereof, the Parties hereto agree that said court in making such determination shall have the power to reduce the scope of such provision to the extent necessary to make it enforceable, and that this Agreement in its reduced form shall be valid and enforceable to the full extent permitted by law.

 

13.                                Governing Law .  This Agreement will be governed by and construed in accordance with the laws of the Commonwealth of Pennsylvania, without regard to any conflict of law principles thereof that would give rise to the application of the laws of any other jurisdiction.

 

14.                                Entire Agreement/No Oral Modifications .  This Agreement constitutes the entire agreement between you and any of the Company Parties with respect to the subject matter hereof and supersedes all prior discussions, negotiations, representations, arrangements or agreements relating thereto, whether written or oral, including but not limited to the Employment Agreement, provided , however , that Sections 6 and 7 of the Employment Agreement shall remain in effect for the duration and on the terms set forth therein.  You represent that in executing this Agreement, you have not relied on any representation or statement not set forth herein.  No amendment or modification of this Agreement shall be valid or binding on the Parties unless in writing and signed by both Parties.

 

*        *        *

 

24


 

IN WITNESS WHEREOF, the Parties have signed this Agreement as of the dates indicated below.

 

Rite Aid Corporation

 

[Executive Name]

 

 

 

 

 

 

 

By:

 

 

 

 

Name:

 

[Executive Name]

 

 

 

 

 

 

Title:

 

Date:

 

 

 

 

 

 

Date:

 

 

 


 

Exhibit 10.2

 

 

This AWARD AGREEMENT, dated as of August 12, 2019 (the “Date of Grant”), is delivered by Rite Aid Corporation (the “Company”) to Heyward Donigan (the “Grantee”).  This agreement evidences the awards made under Section 1 (collectively, the “Award”).  The Award is granted outside the terms of the Rite Aid Corporation 2014 Omnibus Equity Plan (the “Plan”), and the share reserve thereunder, as an “employment inducement award” within the meaning of NYSE Manual 303A.08.  Subject to the terms and conditions herein, the Award will otherwise be subject to the terms and conditions set forth in  the Plan (as amended from time to time as permitted by the Plan) and will be governed as if it had been granted under the Plan.  The terms and conditions contained herein may be amended by the Committee as permitted by the Plan.  Capitalized terms not defined herein shall have the meanings ascribed to them in the Plan.  Your award will post to your  E*Trade brokerage account no later than September 1, 2019.

 

1. Award

 

·       Nonqualified Stock Options

 

Number of Shares:

502,913

Exercise Price per Share:

$7.02

Expiration Date

10 years from date of grant

Vesting Schedule:*

25% on August 12, 2020

 

25% on August 12, 2021

 

25% on August 12, 2022

 

25% on August 12, 2023

 

 

·       Restricted Stock

 

Number of Shares:

284,900

Vesting Schedule:*

33 1/3 % on August 12, 2020

 

33 1/3 % on August 12, 2021

 

33 1/3 % on August 12, 2022

 


*                          Vesting is subject to Grantee’s continued employment through the applicable vesting date, unless otherwise provided in this Award Agreement.

 

1


 

2. Certain Terms and Conditions

 

Adjustment

 

Upon the occurrence of a change in capitalization as described in Section 3(c) of the Plan, the Committee shall, in its sole and absolute discretion, make adjustments in any applicable exercise price and in the number and kind of shares of stock or other property or cash that may be issued under the Award.

 

Withholding

 

Whenever shares of Company Stock are to be delivered pursuant to, or upon the exercise of, an Award, the Company shall have the right to require the Grantee to remit to the Company in cash an amount sufficient to satisfy any federal, state and local withholding tax requirements related thereto or the Grantee may satisfy the foregoing requirement by electing to have the Company withhold from delivery shares of Company Stock having a value equal to the amount of tax required to be withheld upon, up to the maximum statutory rates in the Grantee’s applicable jurisdiction, as determined by the Company.

 

Termination of Employment

 

In General .  Except as otherwise provided herein or in a written employment agreement between the Company and the Grantee, upon the termination of the Grantee’s employment with the Company for any reason prior to the applicable vesting date set forth in Section 1 above, (1) any portion of the Option which had not become vested shall be immediately forfeited by the Grantee, (2) that portion of the Option which had previously become vested shall remain exercisable for a period of 90 days following such termination (but in no event beyond the Expiration Date set forth in Section 1 hereof), and (3) any and all shares of Restricted Stock that had not yet vested shall be immediately forfeited by the Grantee.

 

Termination for Cause . If the Grantee’s employment with the Company terminates for Cause, then (1) all outstanding Options shall terminate and be forfeited at the commencement of business on the date of termination and (2) all outstanding shares of Restricted Stock shall be immediately forfeited by the Grantee.  “Cause” shall have the meaning ascribed to such term in the Grantee’s individual employment, severance or other agreement with the Company or, if the Grantee is not party to such an agreement, “Cause” shall mean conduct that is detrimental to the Company.

 

Post-Termination Exercise Period Upon Certain Terminations .  If the Grantee’s employment with the Company terminates as a result of disability or Retirement, in each case as determined by the Committee, or due to the Grantee’s death, then the portion of the Option which had previously become vested shall remain exercisable for the one year period following such termination (but in no event beyond the Expiration Date set forth in Section 1 hereof).

 

Change in Control .  Upon the occurrence of a Change in Control, this Award shall be subject to the provisions of Section 14 of the Plan.

 

2


 

Entire Agreement; Governing Law

 

The provisions of the Plan are hereby incorporated herein by reference.  The Award Agreement and the incorporated provisions of the Plan constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and the Grantee with respect to the subject matter hereof, and may not be modified except by means of a writing signed by the Company and the Grantee.  If there is a conflict between the terms and conditions of the Plan and the terms and conditions of this Award Agreement, the terms and conditions of this Award Agreement shall govern. This Award Agreement shall be construed and administered in accordance with the laws of the State of Delaware without reference to its principles of conflicts of law.

 

No Guarantee of Continued Service

 

The Grantee acknowledges and agrees that this Award Agreement and the transactions contemplated hereunder do not constitute an express or implied promise of continued engagement as an employee for any period and shall not interfere with the Grantee’s right or the Company’s right to terminate the Grantee’s employment at any time, with or without Cause.

 

Successors and Assigns

 

The terms of this Award Agreement shall be binding upon the Grantee and upon the Grantee’s heirs, executors, administrators, personal representatives, assignees and successors in interest, and upon the Company and its successors and assignees, subject to the provisions of the Plan.

 

Acknowledgement

 

The Grantee and the Company agree that this Award is granted under and governed by the terms and conditions of this Award Agreement, and will otherwise be subject to the provisions of the Plan and will be governed as if it had been granted under the Plan, other than with respect to the share reserve under the Plan which will not be affected by this Award.  The Grantee has reviewed the Plan and this Award Agreement and fully understands all provisions of the Award Agreement including the provisions of the Plan which are incorporated herein by reference.  The Grantee hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee upon any questions relating to this Award Agreement including the provision of the Plan which are incorporated herein by reference.

 

3


Exhibit 99.1

 

 

Press Release

For Further Information Contact:

 

INVESTORS:

MEDIA:

Byron Purcell

Christopher Savarese

(717) 975-5809

(717) 975-5718

 

Rite Aid Appoints Heyward Donigan as Chief Executive Officer

 

CAMP HILL, PA — August 12, 2019 - Rite Aid Corporation (NYSE: RAD) announced today that the Board of Directors has appointed Heyward Donigan as chief executive officer and a member of the Board, effective immediately. As planned, John Standley will step down from his role as chief executive officer in connection with this announcement.

 

“Today’s announcement is an important step in positioning Rite Aid for the future, and we are confident that Heyward is the right person to lead the company in capitalizing on the opportunities in the evolving healthcare environment,” said Bruce Bodaken, chairman of Rite Aid’s Board of Directors. “Over the past several months the Rite Aid Board conducted a thorough search, and Heyward’s strong senior executive experience, proven leadership capabilities and consistent track record of driving profitable growth, as well as her broad healthcare knowledge and digital shopping technology expertise set her apart. Her skillset will be invaluable as we work to deliver on the full potential of our business and create additional long-term value for our shareholders, associates, customers and patients.”

 

“I am deeply honored to have been selected to lead a company with such a strong brand, deep culture and dedicated team of associates. I see tremendous opportunity to revitalize the company’s position as a leader in meeting the health and wellness needs of customers and patients through our store and pharmacy benefit management platforms. I look forward to working with the talented Rite Aid team, as we continue to support the needs of our customers and patients and drive growth, improved performance and shareholder value,” said Donigan.

 

Bodaken continued, “On behalf of the Board, I want to thank John for his numerous achievements in helping to reshape Rite Aid in the face of an evolving environment during his tenure.  In particular, I want to thank him for his leadership in guiding the Company through some incredibly challenging times. His commitment to facilitating a smooth transition for Rite Aid is greatly appreciated, and we wish him the best in his future endeavors.”

 

“I’d like to thank our talented Rite Aid team for their dedication and support in taking great care of our customers and patients throughout my tenure,” said Standley. “I have tremendous confidence in this team and I’m excited about the future prospects of this company.”

 

-MORE-

 


 

Heyward Donigan Biography

 

Heyward Donigan is a recognized leader with 30 years of experience in all aspects of the healthcare industry. She has a passion for building and developing strong teams to deliver innovative offerings in the market.

 

Most recently, Donigan served as the president and chief executive officer of Sapphire Digital (formerly Vitals), which designs and develops omnichannel platforms that help consumers choose their best fit healthcare providers. Since 2015, Donigan lead Sapphire Digital’s strategy and operations to record growth and consumer engagement. Prior to Sapphire Digital, Donigan was president and chief executive officer of ValueOptions, then the nation’s largest independent behavioral health improvement company, where she drove innovation through disciplined execution and grew company revenues to over $1 billion. Previously, Donigan served as executive vice president & chief marketing officer at Premera Blue Cross, where she was responsible for driving profitable growth across the individual, small group, mid-market and national account businesses, and helped the company achieve record growth and profits. Earlier in her career, Donigan served as senior vice president of all operations at Cigna Healthcare. She also held executive roles at General Electric, Empire BCBS and U.S. Healthcare, and previously served on the Board of Directors at several public companies, including Kindred Healthcare.

 

Donigan holds a Master of Public Administration from New York University. She graduated with a Bachelor of Arts in English from the University of Virginia.

 

Inducement Award

 

In accordance with New York Stock Exchange Rules, on August 12, 2019, Rite Aid is announcing that Ms. Donigan will be granted an employment inducement award, consisting of a restricted stock award with a grant date fair value equal to $2,000,000 (which will vest in equal annual installments on each of the three successive anniversaries of her commencement date) and nonqualified stock options with a grant date fair value equal to $2,000,000 (which will vest and become exercisable in equal installments on each of the four successive anniversaries of her commencement date).  These awards were approved by Rite Aid’s Compensation Committee of the Board of Directors effective as of August 12, 2019, as “employment inducement awards” under the NYSE Listed Company Manual Rule 303A.08.

 

About Rite Aid Corporation

 

Rite Aid Corporation, which generated fiscal 2019 annual revenue of $21.6 billion, is one of the nation’s leading drugstore chains with 2,466 stores in 18 states and pharmacy benefit management (PBM) capabilities through EnvisionRxOptions and its affiliates. At Rite Aid we have a personal interest in our patient’s health and wellness and deliver the products and services they need to lead healthier lives. Information about Rite Aid, including corporate background and press releases, is available through the company’s website at www.riteaid.com.

 

2